Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Current Deferred Revenue (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Current Deferred Revenue for 2 consecutive years, with $718000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Deferred Revenue changed N/A year-over-year to $718000.0, compared with a TTM value of $718000.0 through Sep 2025, changed N/A, and an annual FY2020 reading of $2.2 million, changed N/A over the prior year.
  • Current Deferred Revenue was $718000.0 for Q3 2025 at Ovid Therapeutics, roughly flat from $718000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $718000.0 in Q2 2025 and bottomed at $718000.0 in Q2 2025.